Neuropsychiatric lupus

Sultan Qaboos University Medical Journal

Volumn 13, Issue 1, 2013, Pages 19-25

  Alkhotani, Amal ^a  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Nervous system; Neuropsychiatric; Syndrome; Systemic lupus erythematosus (SLE)

Indexed keywords

EID: 84875177500     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: 10.12816/0003191     Document Type: Review

References (38)

1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus 2006; 15:308-18.
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis Rheum 2007; 56:209.
3. Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC. Global trend of survival and damage of systemic lupus erythematosus: Meta-analysis and meta-regression of observational studies from 1950s to 2000s. Semin Arthritis Rheum 2012; 41:830-9.
4. Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. Retrospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69:529-35.
5. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57:496-500.
6. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology 2002; 58:1214-20.
7. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: A study of 41 patients. Neurology 2007; 69:644-54.
8. Bertsias GK, Ioannidis JP, Aringer M, Bolen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-82.
9. Heller T, Ahmed M, Siddiqqi A, Wallrauch C, Bahlas S. Systemic lupus erythematosus in Saudi Arabia: Morbidity and mortality in multiethnic population. Lupus 2007; 16:908-914.
10. AlSaleh J, Jassim V, ElSayed M, Saleh N, Harb D. Clinical and immunological manifestations in 151 SLE patients living in Dubai. Lupus 2008;17:62-6.
11. Ellison D, Gatter K, Heryet A, Esiri M. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol 1993; 46:37-40.
12. Hammad A, Tsukada Y, Torre N. Cerebral occlusive vasculopathy in systemic lupus erythematosus and speculation on the part played by complement. Ann Rheum Dis 1992; 51:550-2.
13. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologic findings in 57 cases, 1956-1977. Semin Arthritis Rheum 1979; 8:212-21.
14. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988; 31:632-41.
15. Afeltra A, Garzia P, Mitterhofer AP, Vadacca M, Galluzzo S, Del Porto F, et al. Neuropsychiatric lupus syndromes: Relationship with antiphospholipid antibodies. Neurology 2003; 61:108-10.
16. Syuto T, Shimizu A, Takeuchi Y, Tanaka S, Hasegawa M, Nagai Y, et al. Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2009; 28:841-5.
17. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:568-71.
18. Liou HH, Wang CR, Chen CJ, Chen RC, Chuang CY, Chiang IP, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5:307-12.
19. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997; 3:377-86.
20. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: Antibodies alter emotion. Proc Natl Acad Sci USA 2006; 103:678-83.
21. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity: Antibody impairs memory. Immunity 2004; 21:179-88.
22. Aranow C, Diamond B, Mackay M. Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36:187-201.
23. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58:1130-5.
24. Matus S, Burgos PV, Bravo-Zehnder M, Kraft R, Porras OH, Farías P, et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J Exp Med 2007; 204:3221-34.
25. Karassa FB, Afeltra A, Ambrozic A, Chang DM, De Keyser F, Doria A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312-24.
26. Okamoto H, Kobayashi A, Yamanaka H. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010:268436.
27. Rhiannon J. Systemic lupus erthematosus involving the nervous system: Presentation, pathogenesis, and management. Clinic Rev Allergy Immunol 2008; 34:356-60.
28. Bosma GP, Huizinga TW, Mooijaart SP, Van Buchem MA. Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus. AJNR Am J Neuroradiol 2003; 24:850-4.
29. Brey RL. Neuropsychiatric lupus: Clinical and imaging aspects. Bull NYU Hosp J Dis 2007; 65:194-9.
30. Appenzeller S, Pike GB, Clarke AE. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2008; 34:361-6.
31. Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:620-5.
32. D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: Good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31:280-5.
33. Łukjanowicz M, Brzosko M. Myelitis in the course of systemic lupuserythematosus: Review. Pol Arch Med Wewn 2009; 119:67-72.
34. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59:120-4.
35. Kimura KY, Seino Y, Hirayama Y, Aramaki T, Yamaguchi H, Amano H, et al. Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord. Intern Med 2002; 41:156-60.
36. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66:470-5.
37. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-33.
38. Jönsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: Increased morbidity but low mortality. Rheumatology (Oxford) 2002; 41:1308-12.